CISD1 and cancer: CISD1 also showed significant positive correlation with MSI in DLBC, HNSC, STAD, LIHC, STES, and GBMLGG (Fig. 8B), suggesting that patients with high CISD1 expression are more likely to benefit from immunotherapies in these cancers.